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ABSTRACT Several in vivo techniques have been devel-
oped to study and measure the uptake of CNS compounds
into the brain. With these techniques, various parameters can
be determined after drug administration, including the blood-
to-brain influx constant (Kin), the permeability-surface area
(PS) product, and the brain uptake index (BUI). These
techniques have been mostly used for drugs that are expected
to enter the brain via transmembrane diffusion or by carrier-
mediated transcytosis. Drugs that have limitations in entering
the brain via such pathways have been encapsulated in
nanoparticles (based on lipids or synthetic polymers) to
enhance brain uptake. Nanoparticles are different from CNS
compounds in size, composition and uptake mechanisms.
This has led to different methods and approaches to study
brain uptake in vivo. Here we discuss the techniques generally
used to measure nanoparticle uptake in addition to the
techniques used for CNS compounds. Techniques include
visualization methods, behavioral tests, and quantitative
methods.
KEY WORDS blood-brainbarrier.braintargeting.CNS
drugs.nanoparticles
INTRODUCTION
Essentially none of the large-molecule pharmaceutics (e.g.
peptides, proteins and nucleic acids) can enter the brain,
and over 98% of small-molecule drugs cannot enter the
brain either (1). In the past few years, several methods to
study brain uptake of drugs have been developed. To
enhance brain uptake, nanoparticles have been used to
target drugs to the brain. Nanoparticles are different from
CNS compounds in size, composition and uptake mecha-
nisms. This has led to different methods and approaches to
study brain uptake in vivo. Here we discuss the techniques
generally used to measure nanoparticle uptake in addition
to the techniques used for CNS compounds.
Drug Transport at the Blood-Brain Barrier
Transport from the blood to the brain is limited by the
blood-brain barrier (BBB). The BBB is formed by brain
endothelial cells that line the cerebral microvessels. It is
supported by other cell types surrounding the endothelium,
such as astrocytes and pericytes (2). These surrounding cells
contribute to the induction of many barrier characteristics
of the endothelium, such as tight junctions, that closely join
the endothelial cells together. Next to being a “physical
barrier,” the BBB is also a “transport barrier.” This aspect
is formed by specific transport proteins and transcytosis
mechanisms that mediate the uptake and efflux of mole-
cules. Third, a “metabolic barrier” is formed by the
expression of metabolizing enzymes such as peptidases,
cytochrome P450 enzymes, and monoamine oxidases (3–5).
All of these barrier functions control and regulate both
inward and outward transfer of molecules between blood
and the brain.
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across the BBB (Fig. 1). Paracellular transport of hydro-
philic molecules is highly restricted by the tight junctions
present between brain endothelial cells.
Lipid-soluble molecules with molecular weights below
400 Da are able to cross by transcellular lipophilic diffusion,
provided that they are not bound to plasma proteins to a high
extent, or form a substrate for a transport system at the BBB.
Based on physicochemical properties, such as molecular
weight and hydrogen bonding, predictions can be made
whether a compound can cross the BBB via this route (6,7).
For a variety of molecules that are essential for brain
function, such as amino acids, glucose, peptides, and
proteins, specific endogenous BBB transporters exist. These
are expressed at both the luminal and the basolateral
membranes of the endothelium (8). These transporters can
be either defined as carriers or receptors.
Carriers are membrane-restricted systems. They are
generally responsible for the transport of small molecules
with a fixed size and mass smaller than 600 Da. Carrier-
mediated transcytosis is used for the delivery of nutrients
such as glucose, amino acids, and purine bases to the brain.
It is substrate selective, and only drugs that closely mimic
the endogenous carrier substrates will be taken up (9).
Endocytosis at the BBB is effectuated through adsorption
or receptor binding. Adsorptive-mediated endocytosis is
initiated by the binding of polycationic substances to
negative charges on the plasma membrane (9). Receptor-
mediated endocytosis is initiated by the binding of a
receptor-specific ligand. Following adsorption or binding,
the substance is internalized and transported via the early
endosome to the lysosome, or transcytosed to the plasma
membrane. The only way for larger molecules and particles
such as antibodies, lipoproteins, proteins and nanoparticles to
be transported into the brain is via receptor or adsorptive-
mediated endocytosis (10), which is different from low-
molecular-weight CNS drugs. When compared to the
peripheralendothelium,thecerebralendotheliumhasamuch
lower endocytotic and transcytotic activity, making BBB
passage of larger molecules difficult even when endocytosis is
possible. In pathological conditions, the transport mechanism
at the BBB might be up- or down-regulated (1).
Next to these influx systems, many efflux mechanisms
exist at the BBB as well. These include P-glycoprotein,
MDR-related protein, ABC transporters, and several others
(1). They restrict entry of molecules into the brain by
promoting luminal release of compounds and are important
in removing harmful substances from the brain, thereby
reducingtoxicsideeffectsofCNSdrugmetabolites.Substrates
for efflux transporters include peptides, lipids, cholesterol,
hormones, CNS drugs, and metabolites (11).
After in vivo administration, most CNS drugs will enter
the brain in their free form via transcellular diffusion.
However, many compounds with psychopharmacological
activity do not posses the right physicochemical character-
istics to be able to cross the BBB. One possible way to mask
these characteristics is to package these compounds in
nanoparticles. Nanoparticles are, of course, much larger
and are only able to enter the brain endothelial cells via
adsorptive or receptor-mediated endocytosis. Subsequent
transcytosis to the basal side of the brain endothelial cells is
required to enter into the brain parenchyma (2). After a
drug or nanoparticle formulation has been administered, the
concentration that can be measured in the brain depends on
several factors, including the plasma concentration-time
curve, the extent of plasma protein binding, the permeability
Fig. 1 Pathways across the
blood-brain barrier (9,12).
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transporters, the metabolic conversion by enzymes, the
binding to membranes or intracellular sites in the brain, and
the continual secretion and drainage of cerebrospinal fluid
(CSF) and brain interstitial fluid (ISF) (5,13).
Many processes are thus involved in uptake and
processing of drugs or particles at the BBB. From a
pharmaceutical point of view, it is interesting to know at
what rate and to what extent uptake occurs. Here we
discuss the different techniques that have been used to
measure uptake of molecules versus methods to asses uptake
of nanoparticles.
IN VIVO TECHNIQUES TO MEASURE COMPOUND
PERMEATION INTO THE BRAIN
An u m b e ro fin vivo techniques have been developed to
measure the uptake of CNS drugs into the brain. These
techniques are routinely performed in rats or mice. Most of
these assays capture the unidirectional uptake phase of a
drug, without assumptions about the fate of the drug after it
has entered the brain (e.g. cellular binding, degradation, and
efflux) (14). Two main parameters for the rate of brain
penetration are often determined: Kin and PS product. Kin is
the unidirectional influx constant from blood to brain. The
PS product (alternatively also referred to as PA product) is
the permeability-surface area product and is a measure of
unidirectional clearance from blood to brain (15). It
represents that volume of plasma which gives up its content
of the particular solute to interstitial fluid per unit time (16).
Both Kin and PS product are expressed in ml/min/g brain.
They are most commonly determined after intravenous
injection or after in situ perfusion of the compound. They can
also be determined in a specific brain region. In addition to
Kin and PS, other pharmacokinetic parameters can be
determined, for example by intracerebral microdialysis.
Finally, brain-specific parameters like the brain uptake index
and the brain/plasma ratio can be determined. The
methods to obtain these parameters are described below.
Kin and PS Product Determination by Intravenous
Injection
The intravenous injection technique is regarded as the gold
standard for brain uptake studies, because it involves fully
physiological conditions (14,17). With this technique, a
(radiolabeled) compound is injected intravenously. Blood is
sampled at various time points. A single brain tissue sample
can be obtained at the terminal time point. Kin can be
obtained using the following equation:
Kin ¼ Q br=AUC 0!T ðÞ ð1Þ
where Kin is the unidirectional influx constant from
blood to brain (ml/min/g brain), Qbr is the
quantity of compound in the brain, without
intravascular content (mass/g brain), and
AUC(0→T) is the integral of plasma concentration
from t=0 to t = T.
Note that Qbr should represent the brain concentration
without intravascular content (14). The higher the drug
concentration at the terminal time point, the more this will
contribute to the concentration that is measured for the
total brain. One way to remove the intravascular content
is by extensively flushing the brain with a (heparinized)
buffer before the brain is taken out. Alternatively, the
intravascular volume can be determined by co-
administration of a vascular marker together with the
drug. The marker is a substance that does not penetrate
the blood-brain barrier, e.g. radiolabeled sucrose. When
such a vascular marker has been included, Qbr can be
calculated using the following equation:
Q br ¼ Q tot   VvCpT ðÞ ð2Þ
where Qtot is the total quantity of compound in the brain,
including vascular content (mass/g brain), Vv is the
brain vascular volume (ml/g), and Cp(T) is the
concentration of compound in the blood at time
point T (mass/ml).
Kin and PS Product Determination by In Situ
Perfusion
The in situ perfusion method complements the iv injection
method. It was originally developed for rats, but it has
been expanded for mice, guinea pigs, and rabbits (18–20).
In the original rat method developed by Takasato et al.
(21), the animal is anesthetised, and after a series of
artery ligations, the perfusion fluid is infused up the
common carotid artery (Fig. 2). Perfusion can be
stopped at a predetermined time point. Similar to the
iv injection method, the perfusion fluid remaining in the
brain can be flushed out, or a vascular marker can be
included in the fluid. The brain is taken out for analysis
of the compound. Kin can be obtained using the following
equation:
Kin¼Q br=CpfT ð3Þ
where Qbr is the quantity of compound in the brain,
without intravascular content (mass/g), Cpf is the
concentration of compound in the perfusion fluid
(mass/ml), and T is the perfusion time.
458 van Rooy et al.If a vascular marker has been included, Qbr can be
calculated similar to the iv injection technique, using the
following equation:
Q br ¼ Q tot   VvCpf ð4Þ
where Qtot is the total quantity of compound in the brain,
including vascular content (mass/g brain), Vv is the
brain vascular volume (ml/g brain), and Cpf is the
concentration of compound in the perfusion fluid
(mass/ml).
The main advantages of the iv injection method are
the ease of injection, the possibility to simultaneously
measure pharmacokinetics, and the fully physiological
conditions, enabling all transporters, junction proteins,
and enzymes to be present at their physiological concen-
tration. The main advantages of the in situ perfusion
method are the ability to tailor the perfusion fluid, the
constant infusion concentration, and the absence of
compound metabolism in other organs (17,22). The Kin
from both the iv injection and the in situ perfusion method
can be converted into the cerebrovascular permeability-
surface area product. From the PS product, permeability P
can be calculated, given that the capillary surface area S is
known. However, usually only the PS product is reported.
PS calculation can be done using the Renkin-Crone
equation:
PS ¼  Fln 1  Kin=F ðÞ ð 5Þ
where PS is the permeability-surface area product (ml/
min/g brain), and F is the cerebral blood or
perfusion flow rate (ml/min/g brain) (23).
Examples of PS product values obtained in vivo range
from 0.0003 ml/min/g for sucrose, a compound that is
considered BBB impermeable, to 1.2 ml/min/g for caffeine
which has a high permeability (24).
Brain Uptake Index (BUI)
The brain uptake index (BUI) represents the relative
uptake of a drug compared to a reference substance
(25,26). The reference is freely diffusible across the BBB,
such as
14C-butanol. The test compound is also radio-
labeled, for example with
3H. A small volume of buffer
containing both the test compound and the reference is
rapidly injected into the common carotid artery of
anesthetised animals (e.g. in the rat 0.2 ml in less than
0.5 s). The bolus passes through the brain in less than 2 s
after injection. After 5–15 s, the brain is isolated, and the
radioactivity in brain tissue and injected buffer is deter-
mined. The BUI can be calculated using the following
equation:
BUI ¼
3Hbrain=
14Cbrain
3Hinjected=
14Cinjected
ð6Þ
The BUI can be expressed as a percentage by
multiplying it by 100. The BUI represents the net uptake
of the drug normalized by the net uptake of the reference
compound. It is therefore a direct function of the single-
pass extraction (E) (27). If the extraction of the reference is
known (for example 100% for butanol (28)), the extraction
of the drug can be calculated:
Edrug ¼ Ereference   BUI ð7Þ
The BUI can be related to the PS product using the
Renkin-Crone equation:
E ¼ 1   e PS=F ð8Þ
The main advantage of the BUI technique is that it is
fast, while its main disadvantage is the low sensitivity.
Additionally, drugs that are taken up slowly cannot be
studied with this method (14).
Examples of BUI values obtained in vivo are 1.4% for
sucrose and 90% for caffeine (24).
Quantitative Autoradiography
Quantitative autoradiography can be used to determine the
amount of radioactive test compound in specific regions of
the brain, such as stroke-affected areas (29) or brain tumors
(30), following oral, intravenous or subcutaneous adminis-
tration to small animals. Blood is sampled at various time
points, and the brain is taken out at the terminal time point.
The brain is subsequently sectioned into 20-μm thick
Fig. 2 Schematic representation of in situ brain perfusion. ACA anterior
cerebral artery. MCA middle cerebral artery. PCA posterior cerebral artery.
Takasato et al. Am J Physiol. 1984 (21). Am Physiol Soc, with permission.
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standards. Intravascular volume can be determined in a
separate experiment using a BBB-impermeable marker,
such as radiolabeled sucrose. Kin and PS product can be
calculated with equations similar to those used for the
intravenous injection method. The strength of quantitative
autoradiography lies in the high spatial resolution in the
micrometer range (14,31).
Microdialysis
Intracerebral microdialysis involves the implantation of a
microdialysis probe in the brain. The probe, which consists
of a semipermeable membrane, is continuously perfused
with a physiological solution. The test drug is administered
to the animal by the desired route (e.g. oral, intravenous or
subcutaneous). Drugs that cross the BBB and enter the
brain interstitial fluid can traverse the semipermeable
membrane by diffusion into the physiological buffer. The
buffer is sampled from the probe, and drug concentration is
measured. The concentration in the sample reflects the
concentration of free drug in the brain. The main
advantage of microdialysis is that brain levels, as well as
blood levels, of the drug can be determined at many time
points in one animal. From these data, pharmacokinetic
parameters can be obtained. Drawbacks include the
technical difficulties of the implantation and the fact that
highly lipophilic compounds are generally difficult to
recover (32).
Brain/Plasma Ratio
Commonly used in the pharmaceutical industry is the
brain/plasma ratio (33). The test drug is administered to
the animal by the desired route. At a predetermined time
point, the blood is sampled and the brain is taken out. The
brain is homogenized and the drug concentration is
determined in both brain and plasma. If multiple animals
were used for multiple time points, the AUC of both the
brain and plasma can be obtained. The brain concentration
is then divided by the plasma concentration. This can be
the ratio of one time point or the ratio of the AUCs (34).
The ratio provides a measure of the extent of brain
penetration, not of the rate of brain penetration. Usually,
the presence of drug remaining in the brain vasculature is
not taken into account.
External Detection Methods
The techniques described so far involve sampling from the
brain. Next to these invasive techniques, several non-
invasive external imaging techniques exist, including posi-
tron emission tomograpy (PET) and single photon emission
computed tomograpy (SPECT). It has been shown that
PET can be used to quantitatively measure the PS product
(35). However, PET and SPECT are in general used for
imaging of transporters, receptors, inflammation, or tumors
in the brain, and not for the uptake of compounds (36–38).
More in-depth information on the advantages and
disadvantages of each of the above-mentioned techniques
can be found in references (14)a n d( 39).
CNS COMPOUNDS VERSUS NANOPARTICLES
As the vast majority of potential CNS compounds have
limited brain uptake, they may benefit from the use of
advanced delivery systems in order to cross the BBB.
Nanoparticles have been widely used as drug carriers to
increase uptake of such drugs into the brain. The drug is
encapsulated in or associated to the particle, thereby
masking its physiochemical characteristics. Particles that
have been used include liposomes, solid lipid nanoparticles,
nanogels,dendrimers, albuminnanoparticles, andpolymeric
particles such as poly(lactic-co-glycolic acid) (PLGA) and
poly(butyl cyanoacrylate) (PBCA) nanoparticles. In many
cases, they are combined with targeting ligands on the
particle surface to enhance uptake. Ligands can include
peptides, proteins, and antibodies. An overview of recent
studies that used nanoparticles to target to the brain in vivo is
given in Table I.
The brain uptake methods described above are excellent
methods to determine the brain uptake of compounds that
are expected to be brain permeable and are taken up by
transcellular diffusion, or for small molecules that will be
taken up by carrier-mediated transcytosis (9). However,
brain uptake of nanoparticles occurs differently from such
small molecules. For most nanoparticles, it has been
demonstrated that brain uptake is initiated by adsorptive
or receptor-mediated endocytosis into brain endothelial
cells. This process is considerably slower than drug
permeation and therefore less compatible with some of
the common methods described above, like the BUI
technique (14).
Of all distribution and kinetic parameters that can be
obtained after drug administration, the PS product is in
many reviews referred to as the best measure of BBB
permeability (5,39). The PS product has been determined
for many substances, including potential CNS compounds
(19), neurotrophic factors (40), and amino acids (41).
However, for nanoparticle formulations, this parameter is
not commonly used. Unlike the BUI method that measures
permeability after seconds, the iv injection method to
measure the PS product allows time points to be selected
according the researcher’s own desire, making the PS
product compatible with nanoparticles, or any other
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462 van Rooy et al.substance for that matter. The reason why this ‘gold
standard’ is not used often in BBB nanoparticle studies
may be because the parameter has been developed for drug
molecules. When the PS product of a drug has been
determined, this is often compared to a brain-impermeable
compound (e.g. sucrose), to a completely permeable
compound (e.g. butanol), or to another existing drug. In
this way, permeabilities of different drugs can be ranked.
When studies are performed using nanoparticles, uptake is
usually not compared to other drugs. The goal will, rather,
be to compare free versus particle-formulated drug or to
compare targeted versus non-targeted particles, regardless of
any encapsulated drug. Only 2 out of 29 studies shown in
Table I included the PS product in their in vivo experiments,
either the PS product of the nanoparticle itself (42) or the
PS product of a loaded drug (43). The other studies use
alternative means of expressing particle uptake into the
brain.
IN VIVO TECHNIQUES TO MEASURE
NANOPARTICLE UPTAKE INTO THE BRAIN
The design of brain uptake studies of free drugs is generally
different from the design of brain uptake studies of
nanoparticles, because the size, physicochemical properties,
and uptake mechanisms are different. These differences
result in different approaches. The methods that have been
used for brain targeting studies using nanoparticles in the
past decade are described here.
Visualization Methods
Microscopy is the most widely used qualitative method to
study BBB uptake of nanoparticles in vivo. Fluorescence
microscopy is often used for its sensitivity. It requires
loading of the nanoparticles with a fluorescent dye (62)o r
covalent coupling of the particle building blocks to a dye
(59). Commonly used fluorescent dyes include rhodamine-
123, fluorescein, and 6-coumarin. Particles are usually
injected iv, and after sectioning the brain, they can be
localized using fluorescence microscopy. The brain endo-
thelium can be visualized by using an endothelium staining
marker such as lectin. If such a marker is included in the
staining procedure, a distinction can be made between
particles that are associated with the brain endothelium,
and particles that have crossed into the brain parenchyma
(68).
If gene delivery to the brain is of interest, a plasmid
expressing a fluorescent protein can be incorporated into
the particle, and gene expression can be assessed by
visualizing protein fluorescence in the brain sections
(57).
Next to fluorescence microscopy, electron microscopy is
commonly used. With this technique, single particles can be
visualized in specific regions of the brain. For example,
Zensi et al.( 53) showed that human serum albumin
nanoparticles could be detected by electron microscopy in
murine brain sections after iv administration. In the
electron microscopic pictures, a distinction can be seen
between particles in the capillary lumen, particles within
the endothelial cells (Fig. 3), and particles that have been
taken up into neuronal cells.
Besides microscopic section imaging, in vivo fluorescence
imaging can be used to visualize uptake of particles into the
brain (56,57). In vivo fluorescence imaging involves labeling
of the particles with a fluorophore. A sensitive camera
detects the fluorescence emission in the whole body of a
living small animal. Fluorescent labels that absorb in the
near-infrared region are generally preferred, because they
limit tissue autofluorescence (71,72).
Fluorescence intensity in the brain area can be com-
pared between different nanoparticle formulations to
determine which formulation shows the highest brain
Fig. 3 Micrographs of the cortex
region of mice after injection of
Apo E-modified HSA nanopar-
ticles. Fifteen min after intravenous
injection, the nanoparticles (dark
spheres indicated by arrows)
could be seen inside the endo-
thelial cells. Figure 3a shows a
cross-section of a blood vessel
with two nanoparticles in the
endothelial cell and one nano-
particle still in the lumen of the
vessel. Figure 3b shows a higher
magnification of the same micro-
graph. Reprinted from Journal of
Controlled Release (53). Copy-
right (2009), with permission from
Elsevier.
In Vivo Methods to Study Uptake of Nanoparticles into the Brain 463accumulation (73). Although in vivo imaging is a rapidly
progressing field, detection is at present not sensitive
enough to visualize the particles within the microenviron-
ment of the brain, or to provide quantitative information
on the usually low concentrations that have accumulated in
the brain.
Behavioral Tests
Some drugs that act on the CNS are unique compared to
drugs that act on any other organ, because of their ability
to interfere with brain signaling and to induce specific
behavioral effects. This gives rise to the possibility of not
only detecting the level of compound that reaches the
brain, but also to determine whether the compound has a
pharmacodynamic effect. Drugs that normally do not enter
the brain can be encapsulated into nanoparticles to be
transported over the BBB. The effect of the drug in the
brain can be read out by monitoring the behavior of the
animal with specifically designed behavioral tests.
These tests do not register the whole particle inside the
brain, but only the free drug that has been released from
the particle, as only the free drug will be able to exert an
effect. Drug release from nanoparticles at the site of interest
is crucial; therefore, behavioral tests are of great value.
Nociceptive Tests
A common model drug that has been used in combination
with nanoparticles is the opiate antagonist loperamide.
Intracerebral administration of loperamide causes antino-
ciceptive effects. However, after iv injection of loperamide,
these effects are not seen. This is due to the efflux
membrane transporter P-glycoprotein (74). Loperamide
molecules that reach the endothelial cells of the blood-
brain barrier are rapidly transported back to the blood
circulation. Therefore, loperamide is not able to enter into
the brain parenchyma, making it a model drug for
nociceptive testing. It can be loaded inside nanoparticles
(60) or simply adsorbed onto the surface of the particles
(52). Loperamide-containing particles that are successfully
taken up by the brain can release their drug content in the
brain, causing an analgesic effect of loperamide after iv
administration (54). Similar to loperamide, the hexapeptide
dalargin has been used for this purpose (67).
To measure nociception, two basic tests have been
developed for the use in rats and mice: the tail flick test
and the hot plate test. These tests are convenient, because
they apply to healthy wild-type animals, requiring no
disease induction or transgenic animals. Both tests measure
the response to a painful thermal stimulus. In the tail flick
test, a light beam is used to apply heat to a small area of the
tail. Latency (time) to flick the tail out of the path of the
light beam is measured. In the hot plate test, the animal is
placed on the surface of a hot plate. Latency to lick the
forepaws or to lift one of the hindpaws is recorded. In both
tests, latency is usually determined before administration of
the drug to determine the background response, and after
administration of the drug at one or several time points. To
avoid damage if the animal does not respond, a cut-off time
is predetermined, typically between 10 and 60 s (54,60,75).
This time point is regarded as the maximal possible
effect (MPE) (76). The experimental response latencies
are usually expressed as percent maximal possible effect
(%MPE), which can be calculated using the following
formula:
%MPE ¼
postdruglatency   predruglatency
cutoff time   predruglatency
  100%
ð9Þ
It should be noted that these tests can only be performed
with model (analgesic) compounds. The characteristics of
other drugs may be different from the tested analgesic. If
another drug is used in combination with the nanoparticles,
the encapsulation, formulation, and subsequent brain
uptake may be different from the model compound.
Motor Function and Learning and Memory Tests
Other models that allow for behavioral testing often include
induction of disease states in animals, like MPTP-induced
Parkinson syndrome. Drugs that treat these syndromes, but
normally do not penetrate the BBB in their free form, are
candidates for nanoparticle formulation to enhance brain
uptake. An example is nerve growth factor (NGF) (47).
NGF has been evaluated for the treatment of neurological
diseases such as Alzheimer’s disease and Parkinson’sd i s e a s e .
However, NGF has a low permeability through the BBB
followingintravenousadministration(40). Kurakhmaeva et al.
(69) tested MPTP-treated animals for improvement in
symptoms of parkinsonism after iv administration of a
NGF nanoparticle formulation. The NGF PBCA nano-
particles lead to a significant reduction in symptoms,
including rigidity, tremor, locomotor activity, and
orientation-research reaction.
Finally, transgenic mice like the APP/PS1 Alzheimer’s
disease mice can be used to determine behavioral skills
(77). The Cu/Zn-selective metal chelator clioquinol (CQ),
which has a poor BBB penetration, has been encapsulated
into PBCA nanoparticles by Kulkarni et al.t oi m p r o v e
brain uptake (70). The transgenic mice can be tested with
the Y-maze test for improvement in cognitive behavioral
skills. Furthermore, brains of Alzheimer’sd i s e a s em i c e
can be histologically stained for decrease in amyloid
plaques.
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Quantitative methods to study BBB nanoparticle uptake
in vivo involve determination of pharmacokinetic (PK)
parameters and biodistribution studies. For both of these
studies, either the particle itself or an entrapped compound is
labeled. Most commonly, radioisotopes like
3H,
14Co r
125I
areused.Alternatively,theentrappedcompoundisquantified
by HPLC.
Pharmacokinetic Parameters
In most brain targeting studies, the nanoparticles are
administered intravenously. The goal of a pharmacoki-
netic study is to assess the fraction of the administered
dose that is distributed to the brain or is excreted from
the body (78). Nanoparticle and/or drug concentrations
are measured in the blood (plasma) and in the brain at
several time points after administration. From these
measurements, the area under the concentration-time
curve (AUC) can be obtained for both blood and brain.
Pharmacokinetic models quantify the rate and extent of
the distribution by mathematically analyzing these data. In
this way, a number of PK parameters can be obtained.
Commonly, several of these parameters are determined
f o re i t h e rb l o o d( 51,55) ,b r a i no rb o t h( 49,50). Other
organs can also be included in the PK study (62). In
current brain targeting studies, the most widely deter-
m i n e dP Kp a r a m e t e r si nb o t hb l o o da n db r a i na r eC max,
peak concentration; Tmax, time to reach peak concentra-
tion; AUC, area under the concentration-time curve, from
the time of injection (t=0) to a determined time point t
(AUC(0→t)) or extrapolated to infinity AUC 0!1 ðÞ

;H a l f -
life (t1/2), time it takes for 50% to be eliminated; and
Mean Residence Time (MRT), the average time a
compound remains in the blood or brain.
Biodistribution Studies
For biodistribution studies, the nanoparticles are usually
administered intravenously. After administration, the
animals are sacrificed at a specific time point, or
preferably at several time points. The brain is taken
out, along with some of the major organs where the
particles are likely to end up, including liver and spleen.
If a β-emitting label is used, organs can be dissolved, and
radioactivity can be determined by liquid scintillation
counting. If a γ-emitting label is used, organs can be
directly counted in a γ counter. If the compound itself is
to be detected, a tissue extraction can be performed,
followed by HPLC determination of the concentration.
The amount of drug that was found in the brain and
other organs can be represented as mass/organ or mass/
gram. In this way, the increase in brain uptake compared
to the control sample is obtained. Along with the
experimental samples, the injection sample, as it was
administered to the animals, can be assayed for drug
content using the same analytical method, so that the
amount of drug taken up into the brain can be expressed
as a percentage of the injected dose (%ID). For example,
Ke et al.( 56) performed a biodistribution study in mice
using dendrimers, which were either unmodified or
modified with an angiopep-2 targeting ligand. They found
0.03%ID in the brain for the unmodified dendrimers and
0.25%ID for the angiopep-2 modified dendrimers. This
shows the importance of targeting ligands in enhancing
brain uptake of nanoparticles. The absolute increase
owing to the targeting ligand (over 8 times more) can be
exactly assessed by such a biodistribution study.
DISCUSSION
Each method to determine brain uptake of compounds or
nanoparticles has advantages and disadvantages. In this
section we discuss the possibilities and limitations of the
methods.
Percentage of Maximal Possible Effect
As described above, in nociceptive studies the outcomes are
usually represented as time to respond, commonly
expressed as the percentage of maximal possible effect
(%MPE). This parameter tells whether the encapsulated
drug has an effect in the brain, but it provides no
information on the amount of drug that was taken up.
Therefore, it is difficult to compare different formulations
or studies. For example, it cannot be concluded that a
formulation resulting in 20% MPE, has a two-fold higher
brain uptake of the drug than a formulation resulting in
10% MPE. Moreover, formulations that are successfully
targeted to the brain will often reach 100% MPE (52,54).
This low dynamic range makes it difficult to distinguish
between various formulations. In general, the %MPE will
provide an indication whether a formulation works to a
higher, moderate, or insignificant extent, rather than
provide exact drug uptake values.
Percentage of Injected Dose
When a biodistribution study has been performed, present-
ing the mass of drugs or particles in the brain is frequently
preferred over presenting the %ID (see Table I), although it
usually provides less information on the extent of uptake
into the brain. The reason for this preference is not always
clear. It may lie in the fact that the percentages that are
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to other organs. While targeting to the liver can result in
75%ID in the liver (79), and targeting to a tumor can
produce values around 10% ID/gram tumor (80,81),
percentages that are found in the brain are often below
0.5% and can be as low as 0.01% ID/g brain (43).
Although low, uptake may nonetheless be manifold higher
compared to an impermeable control. If a low %ID is
found, it raises the question what %ID is actually needed to
produce an effect. Although this depends on the drug that is
eventually going to be used in combination with the
nanoparticle for therapeutic purposes, the percentage
needed may not be that high. In general, low concen-
trations of drugs are sufficient in the brain to result in a
therapeutic effect. For example, only about 0.02% of a
peripherally administered dose of morphine enters the
brain, but that is sufficient to produce analgesia. For most
CNS therapeutics on the market, less than 0.2% of the
peripheral dose is taken up into brain (82). When
transferrin is used as a targeting ligand, brain uptake in
vivo is limited due to high endogenous concentrations of
transferrin in the blood (9). Nevertheless, loperamide-
loaded nanoparticles coupled to a transferrin targeting
ligand are able to produce significant analgesia compared
to non-targeted nanoparticles (54), demonstrating that low
levels of uptake in the brain can be sufficient to produce
adequate therapeutic effects.
In general, the percentages of the injected dose found in
the brain after targeting of nanoparticles are highly
variable. As shown in Table I, the %ID generally ranges
from 0.01% to 0.5% in case an intravascular content
correction (see below) was applied (42,43,45,47,48). In case
no intravascular content correction was applied, recorded
percentages can be over 15%ID, of which the vascular
contribution is unclear (51,64,65,69).
If the %ID is plotted, notion should be taken whether
this is %ID/organ or %ID/gram. This also holds for mass/
organ or mass/gram. For example, a 20–25 g Balb/c
mouse has an average brain weight of about 0.4 g. If a
brain dose of 1% ID/g is recorded, the actual percentage of
the injected dose in the brain is 0.4%. Therefore, it makes
little sense to provide the %ID/gram. In the adult rat,
however, the average brain weight is above 1 g, making this
expression way more realistic.
Intravascular Content
As mentioned before, particles that are still present in the
circulation at the time of sacrifice can contribute to a
significant degree to the amount of drug measured in whole
brain homogenate. Twomethods to correct for intravascular
content exist. They are brain perfusion with a buffer and
inclusion of a vascular marker.
Ifadministrationofthenanoparticlesisperformedbyin situ
perfusion, which is usually done under anesthesia, buffer
perfusion can be performed directly after infusion of the
nanoparticle solution. If the particle administration is
performed by iv injection, perfusion can be performed after
subsequent anesthesia or directly after sacrifice. In that case,
it is recommended to include an anti-coagulant, such as
heparin, in the buffer to prevent perfusion obstruction by
coagulated blood in the microvasculature.
The vascular washout fluid is usually administered either
through the jugular vein or transcardially through the left
ventricle of the heart. It should be noted that administra-
tion through the heart will result in most of the perfusion
fluid distributing to the rest of the body instead of to the
brain, if no vessels are clamped. Therefore, in most cases,
the aorta is clamped, causing more of the fluid to reach the
carotid arteries. Even so, only 10% of the fluid that reaches
a common carotid artery reaches the brain if no additional
ligations are placed on the external carotid artery and the
pterygopalatine artery (25). This should be taken into
account when performing a vascular washout, and a
sufficient volume should be perfused to ensure that brain
vasculature is washed completely. In general, when in situ
perfusion is performed with external carotid artery and
pterygopalatine artery ligated, perfusion of 1 to 5 ml buffer
is considered sufficient (22). When transcardiac perfusion is
performed with the descending aorta clamped, 20 ml of
buffer is commonly used, as is shown in Table II. Outflow
of the perfused fluid can be realized by severing the jugular
veins (83,84) or cardiac ventricles (22). Optionally, outflow
can be monitored to ensure thorough washout (45,47).
The second intravascular content correction method is
co-administration of a vascular marker. The marker is a
substance that does not penetrate the blood-brain barrier,
e.g. radiolabeled sucrose. This allows for the determination
of the total vascular volume in the brain. As described
above (Eqs. 2 and 4), brain vascular blood concentration
can be subtracted from the total brain concentration,
yielding the amount of particles that is associated with the
brain endothelial cells and brain parenchyma. The brain
vascular volumes of mice and rats have been determined in
many studies, as shown in Table III. Typically, this volume
ranges between 11 and 14 μl/gram brain and is on average
about 12 μl/gram for both mice and rats.
Correction for vascular content is in many studies not
applied. If the concentration of drugs or particles in the
blood is sufficiently low, this may not pose a problem.
Otherwise, the quantitative amount or %ID found in the
brain is likely to be overestimated. To gain insight in the
blood background, it is necessary to measure the blood
concentration at the time of sacrifice. Due to clearance, the
concentration of circulating particles is generally highest at
the first time point measured and will decrease at later time
466 van Rooy et al.points. If no vascular content correction is applied, the
concentration measured in the brain is likely to be highest
at the first time point and to decrease as well, due to the
blood background. In this case, the brain:blood ratio can be
provided in addition to the amount or %ID in the brain
(70). If this ratio remains constant over the measured time
points, it cannot be concluded that brain uptake was
highest at the earliest time point.
Similarly, this holds for experiments in which compara-
ble types of nanoparticles were included, e.g. targeted and
non-targeted particles. The concentration in the brain as
well as in the blood can be measured for both particle
types. The increase in the brain:blood ratio reflects the
increase of brain binding/uptake of the targeted particles
compared to the non-targeted particles. In this way,
contribution of the targeting ligand to the brain uptake of
the particle can be seen, although the quantitative amount
found in the brain may be overestimated. In most cases the
same type of particle is used for both targeted and non-
targeted samples. Therefore, circulation times of both
particles are often comparable.
As the brain vascular volume for mice and rats is usually
about 12 μl/gram brain, this provides an estimate to subtract
the brain vascular concentration from the total brain
concentration.Of course, blood concentration at the terminal
time point needs to be measured in order to accomplish this.
Although not common, this approach can be used (87,90).
Capillary Depletion
If the brain is taken out for analysis, the nanoparticle content
that is not present within the blood of the brain microvascu-
lature may be bound to the endothelium, be present within
the endothelial cells or be transcytosed to the brain paren-
chyma (39). A distinction can be made between endothelial-
associated particles and particles that have transcytosed into
the brain parenchyma by performing a capillary depletion
(93,94). This technique involves homogenization of the brain,
followed by dextran density centrifugation to deplete the
homogenate of its vasculature. The nanoparticles can be
detected in both the parenchyma and the capillary fraction. It
should be noted that particles which are bound to the surface
Table II Vascular Washout Times and Volumes That Have Been Used in Mice and Rats to Clear the Brain from Intravascular Content
Species Nanoparticle or drug administration Washout administration Clamps or ligations Washout volume Washout time Ref
Rats common carotid artery common carotid artery common carotid and external
carotid arteries
1–5m l 1 0 –15 sec (22)
Rats femoral vein jugular arteries none 15–20 ml 30 min (47)
Rats common carotid artery common carotid artery common carotid, external carotid,
and occipital arteries
20–30 ml 120–180 sec (59)
Rats femoral vein carotid artery carotid artery 30–35 ml 60 min (45)
Rats tail vein heart none 50 ml 10 min (48)
Mice common carotid artery common carotid artery common carotid artery 1.15 ml 60 sec (85)
Mice tail vein heart none 2 ml 2 min (61)
Mice jugular vein heart descending aorta 20 ml 30 sec (83)
Mice heart heart descending aorta 20 ml <1 min (86)
Mice jugular vein heart descending aorta 20 ml 1 min (87)
Mice jugular vein heart descending aorta 20 ml 1–2 min (84)
Mice jugular vein jugular vein none 50 ml – (53)
Species Method Vascular volume
(μl/gram brain)
Ref
Rats (200–400 g) Femoral vein injection of [
14C]sucrose 12.5±0.7 (88)
12.9±1.6
12.2±0.8
Rats (220–330 g) In situ perfusion of [
14C]sucrose 12±1.9 (23)
Rats (220–330 g) In situ perfusion of [
14C]sucrose 13.3±3.4 (89)
Rats In situ perfusion of [
14C]sucrose 12±2 (90)
Mice (20–25 g) In situ perfusion of [
3H]inulin 11.4±0.4 (19)
Mice (20–25 g) In situ perfusion of [
14C]sucrose 11–14 (91)
Mice
(8–22 weeks)
In situ perfusion of [
14C]sucrose 11.9±2.6 (92)
12.8±1.2
Table III Brain Vascular Volumes
That Have Been Found in Mice
and Rats After Administration of a
Vascular Marker
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capillaries during centrifugation, and therefore end up in the
parenchyma fraction. This may be prevented when the brain
vasculature is flushed before the brain is taken out to remove
the low affinity bound particles. Particles bound with high
affinity to the capillaries should remain associated.
Sampling Time Points
The time points that are chosen to measure brain uptake or
drug effect are commonly between 15 min and 24 h. In most
cases the earliest time points, between 15 min and 2 h, yield
the highest uptake or effect (Table I). After that, the amount
of particles measured in the brain generally decreases. This
may be due to degradation of the particles, followed by
elimination of the label or encapsulated drug by degrada-
tion, metabolism, efflux, and permeation through the brain
capillaries (95). In many cases, the particle concentration in
the brain is highly decreased or undetectable after 24 h
(55,62). Measurements at later time points are preferably
performed with stable compounds. If a metabolizing drug is
used for detection, the concentration in the body will be
decreased to undetectable levels at later time points (65).
Intravenous Administration Routes
As mentioned before, nanoparticles are administered intra-
venously in most studies. The most convenient way to
accomplish this is by administration in the tail vein. Other iv
administration routes that have been used for brain targeting
studies include the femoral vein, the jugular vein, and the
carotid artery. Reddy et al.( 63) demonstrated that the site of
iv administration can have significant influence on the
uptake of nanoparticles in the brain. They used a rat model
and administered 0.5 ml of a nanoparticle dispersion either
through the tail vein, the jugular vein, or the internal carotid
artery. After one hour, administration via the internal
carotid artery resulted in a 13-fold greater uptake of
nanoparticles in the brain compared to either tail or jugular
vein administration. The reason may be decreased exposure
of the particles to the reticulo-endothelial system, resulting in
an increased concentration of circulating particles available
for brain uptake. Although administration via the internal
carotid artery is technically more difficult, this finding is
worthwhile to take into account in BBB targeting studies.
CONCLUSION AND FUTURE PROSPECTS
In recent brain targeting studies involving nanoparticles, a
wide range of approaches has been used by researchers to
determine the extent, rate, and effect of drug and nano-
particle uptake into the brain. Choosing the right method
depends on whether you want to obtain quantitative uptake
values, visualize the uptake mechanism, or test a drug effect.
Each technique has its own advantages and disadvantages
which should be considered before experiments are started.
Many parameters, like administration route, sampling time
points,andthewayinwhichthedataarepresented,shouldbe
taken into account. Because contribution of cerebral vascular
content can be high, it is recommended to determine the
amount of drugs or particles present in the blood at the
terminal time point and to properly correct for this.
Many studies have shown that nanoparticles can reach the
brain. Within the brain microenvironment, targeting of
nanoparticles starts with binding and uptake of the particles
into the endothelial cells. By using techniques such as brain
capillary depletion or electron microscopy, it can be shown
thatparticleshavecrossedtheendothelialbarrierandreached
the brain parenchyma. However, the intracellular fate of
nanoparticles in vivo often remains unclear. This is due to
limitations of in vivo detection methods and techniques.
Therefore, intracellular processes such as endocytotic mech-
anisms currently have to be studied in vitro (96,97)i na n
artificial environment. Progress in the field of in vivo detection
methods is ongoing (98,99). In the future, faster and more
sensitive detection methods are required to study uptake and
trafficking of nanoparticles within the brain.
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